Patent SG-11201908492P-A (SG)
Title: Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
Inventor: LEONG JUN
IPC: A61K38/00
Filed: 2018-03-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) omits I iolo MIME 011 (10) International Publication Number WO 2018/183385 Al WIPO I PCT (51) International Patent Classification: A61K 35/17 (2015.01) CO7K 14/725 (2006.01) A61K 38/00 (2006.01) CO7K 14/705 (2006.01) AO1N 63/00 (2006.01) Cl 2N 5/0783 (2010.01) (21) International Application Number: PCT/US2018/024650 (22) International Filing Date: 27 March 2018 (27.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/477,335 27 March 2017 (27.03.2017) US 62/628,774 09 February 2018 (09.02.2018) US (71) Applicants: NATIONAL UNIVERSITY OF SINGA- PORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). NKARTA, INC. [US/US]; 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). (72) Inventors: LEONG, Jun, Hao; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SHIMASAKI, Noriko; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SEOW, See, Voon; c/o National University Of Sin- gapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). CAMPANA, Dario; c/o National University Of Sin- gapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TRAGER, James, Barnaby; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). LAZETIC, Alexandra, Leida Liana; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). GUO, Chao; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). BUREN, Luxuan, Guo; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). MASRANI, Shyam, Sashikant; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). (74) Agent: CARROLL, Alice, 0. et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd., P.O. Box 9133, Concord, MA 01742-9133 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL KILLER CELL IM- = MUNOTHERAPY W O 20 18/ 183385 Al (57) : Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as can- cerous cells or those affected by an infectious disease. Several em- bodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell com- positions to treat diseases are also provided for in several embod- iments. CD3c FIG. 1 B [Continued on next page] WO 2018/183385 Al MIDEDIMOMOIDEIREEMOMOHIMEMOIMMIS TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))